CRTX Cortexyme Inc.

36.24
-2.56  -7%
Previous Close 38.8
Open 39.43
Price To Book 9.22
Market Cap 1,065,537,178
Shares 29,402,240
Volume 167,905
Short Ratio
Av. Daily Volume 148,283
Stock charts supplied by TradingView

NewsSee all news

  1. Cortexyme to Present at the LifeSci Capital Alpha Series Virtual Conference on April 9, 2020

    -- Presentation to be webcast on Cortexyme's website -- Cortexyme, Inc. (NASDAQ:CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what it believes to

  2. Cortexyme Presents Data Supporting Role of P. Gingivalis in Alzheimer's Pathology at Advances in Alzheimer's and Parkinson's Therapies Virtual Focus Meeting 2020

    -- New results demonstrate P. gingivalis' ability to infect neurons and cause characteristic Alzheimer's pathology -- Cortexyme's lead compound, COR388, targets gingipains produced by P. gingivalis and is currently

  3. Cortexyme Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

    — Following initial public offering and private placement, Cortexyme is well capitalized and focused on high quality execution of the Phase 2/3 GAIN Trial — Interim analysis for the GAIN Trial on track to be

  4. Cortexyme Announces Gain Trial in Alzheimer's Disease Has Reached Enrollment Milestone of 300 Patients

    - Sub-study shows greater than 90% of enrolled patients have moderate to severe periodontal disease, indicating relevance to mechanism of action against P. gingivalis - Interim analysis of the Phase 2/3 GAIN Trial

  5. Cortexyme Provides Regulatory Update for COR388 Development Program in Alzheimer's Disease

    - Interim analysis in the Phase 2/3 GAIN Trial expected to occur in Q4 2020 Cortexyme, Inc. (NASDAQ:CRTX) today provided an update on its clinical development plans for COR388, the company's lead investigational

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2/3 interim analysis to occur 4Q 2020. Final data due 4Q 2021.
COR388 - GAIN
Alzheimer’s disease

Latest News

  1. Cortexyme to Present at the LifeSci Capital Alpha Series Virtual Conference on April 9, 2020

    -- Presentation to be webcast on Cortexyme's website -- Cortexyme, Inc. (NASDAQ:CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what it believes to

  2. Cortexyme Presents Data Supporting Role of P. Gingivalis in Alzheimer's Pathology at Advances in Alzheimer's and Parkinson's Therapies Virtual Focus Meeting 2020

    -- New results demonstrate P. gingivalis' ability to infect neurons and cause characteristic Alzheimer's pathology -- Cortexyme's lead compound, COR388, targets gingipains produced by P. gingivalis and is currently

  3. Cortexyme Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

    — Following initial public offering and private placement, Cortexyme is well capitalized and focused on high quality execution of the Phase 2/3 GAIN Trial — Interim analysis for the GAIN Trial on track to be

  4. Cortexyme Announces Gain Trial in Alzheimer's Disease Has Reached Enrollment Milestone of 300 Patients

    - Sub-study shows greater than 90% of enrolled patients have moderate to severe periodontal disease, indicating relevance to mechanism of action against P. gingivalis - Interim analysis of the Phase 2/3 GAIN Trial

  5. Cortexyme Provides Regulatory Update for COR388 Development Program in Alzheimer's Disease

    - Interim analysis in the Phase 2/3 GAIN Trial expected to occur in Q4 2020 Cortexyme, Inc. (NASDAQ:CRTX) today provided an update on its clinical development plans for COR388, the company's lead investigational

  6. Cortexyme Announces Closing of $125 Million Private Placement

    Cortexyme, Inc. (NASDAQ:CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat Alzheimer's and other degenerative diseases, today announced that it has

  7. Cortexyme Announces $125 Million Private Placement

    Cortexyme, Inc. (NASDAQ:CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat Alzheimer's and other degenerative diseases, today announced that it has

  8. Cortexyme Announces Publication of New Data Further Demonstrating the Therapeutic Potential of COR388, the Company's Lead Investigational Medicine

    -- Data in aged dogs shows oral dosing of COR388 results in target engagement, reduction of bacterial load and beneficial effects on downstream pathology -- Lysine-gingipains from P. gulae were found in the neurons

  9. Cortexyme Announces the Initiation of an Open-Label Extension Study for the GAIN Trial of COR388 in Alzheimer's Disease

     – Open-label extension study will provide COR388 to patients for an additional 48 weeks – GAIN Trial to continue as planned following pre-specified DMC safety data review Cortexyme, Inc. (NASDAQ:CRTX), a clinical

  10. Cortexyme to Present at the 3rd Annual Neuroscience Innovation Forum on January 12, 2020

    – Corporate presentation by CEO Casey Lynch will be webcast live – Lynch will also participate in a roundtable session earlier in the day Cortexyme, Inc. (NASDAQ:CRTX), a clinical stage biopharmaceutical company

  11. Cortexyme Announces Presentation of Data Revealing Link Between Bacterial Pathogen and Genetic Risk for Alzheimer's Disease

    – In a Phase 1b trial, COR388 reduced levels of fragmented ApoE protein in cerebrospinal fluid of subjects with Alzheimer's – –The drug's target, the gingipains from P. gingivalis bacteria, preferentially attack the

  12. Cortexyme to Present at the Evercore ISI 2nd Annual HealthCONx Conference on December 3, 2019

    -- Presentation to be webcast on Cortexyme's website -- Cortexyme, Inc. (NASDAQ:CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what it believes to

  13. Cortexyme Announces Third Quarter 2019 Financial Results and Provides Business Update

    — Lead investigational medicine COR388, a potentially transformative new paradigm for addressing Alzheimer's disease, continues to advance in Phase 2/3 GAIN clinical trial — Following successful May 2019 initial

  14. Cortexyme Announces Oral Presentation on COR388 at Clinical Trials on Alzheimer's Disease 2019

    - Presentation will detail impact of Cortexyme's lead compound, COR388, on ApoE in Alzheimer's Disease patients - CTAD attendees are also invited to educational session focused on Cortexyme's new investigational

  15. Cortexyme Announces European Screening Now Underway in the Phase 2/3 GAIN Trial

    - International study is evaluating whether a new investigational medicine targeting P. gingivalis bacteria can slow or halt the progression of Alzheimer's disease - GAIN Trial opened for U.S. enrollment in Q2 2019